Delving into the Latest Updates on Baicalin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Wild Baicalin

Target

KDM1A

Action

inhibitors

Mechanism

KDM1A inhibitors(Lysine-specific histone demethylase 1 inhibitors), Epigenetic drug

Therapeutic Areas

Digestive System DisordersNeoplasmsImmune System Diseases+ [6]

Active Indication

HepatitisAcute kidney injury due to sepsisLiver Diseases, Alcoholic+ [6]

Inactive Indication

Hepatitis C

Originator Organization-

Active Organization

Ganzhou People's Hospital

Fujian University of Traditional Chinese Medicine

Beijing University of Agriculture

+ [9]

Inactive Organization

Tsumura & Co.

License Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC21H18O11

InChIKeyIKIIZLYTISPENI-ZFORQUDYSA-N

CAS Registry21967-41-9

Scutellaria baicalensis extracts (SBE) have demonstrated potential therapeutic effects against gastrointestinal disorders. This study evaluated the effects of SBE on zymosan-induced irritable bowel syndrome (IBS) symptoms and the underlying mechanisms involved. The major components of SBE, baicalin and baicalein, were quantified using high-performance liquid chromatography. SBE inhibited pacemaker potentials in interstitial cells of Cajal in vitro, with an IC₅₀ value of 27.48 μg/mL. In an animal model of IBS, SBE administration restored colonic length, weight, and stool consistency. Furthermore, SBE reduced tumor necrosis factor-α expression and alleviated pain-associated behaviors. Histological analysis revealed that SBE treatment restored normal colon tissue structure and significantly reduced inflammation. Electrophysiological recordings demonstrated that SBE inhibited the activity of transient receptor potential (TRP) channels, including TRPV1, TRPV4 and TRPA1, as well as voltage-gated sodium channels (NaV1.5), which are associated with visceral pain hypersensitivity. These findings suggest that SBE has therapeutic potential, making it a promising candidate for the management of IBS.

31 Dec 2025·RENAL FAILURE

Baicalin alleviates sepsis-associated acute kidney injury through activation of the PPAR-γ/UCP1 signaling pathway

Article

Author: Zhu, Xue-Xue ; Sun, Hai-Jian ; Huang, Qiu-Ya ; Gu, Xin ; Gu, Ming-Jia ; Yu, Xiang ; Yu, Ya-Fen ; Bao, Neng ; Wang, Jin ; Lu, Qing-Bo

PURPOSE:

This study aims to investigate the protective effect of baicalin on sepsis-associated acute kidney injury (SA-AKI) and its molecular mechanism.

MATERIALS AND METHODS:

An SA-AKI mouse model was established via lipopolysaccharide (LPS) injection. Baicalin's effects on renal function, oxidative stress, and apoptosis were evaluated using histopathology, dihydroethidium, and terminal deoxynucleotidyl transferase dUTP nick end labeling staining. Bioinformatics, molecular docking, ribonucleic acid (RNA) sequencing, and Western blotting were employed to investigate the role of baicalin in regulating the peroxisome proliferator‑activated receptor‑γ (PPAR-γ)/uncoupling protein 1 (UCP1) pathway. Human kidney-2 cells were used for in vitro validation.

RESULTS:

In this study, baicalin significantly ameliorated LPS-induced acute kidney injury by modulating the PPAR-γ/UCP1 signaling pathway. Both in vivo and in vitro experiments revealed that baicalin attenuates inflammation, oxidative stress, and apoptosis while restoring mitochondrial function. RNA sequencing analysis revealed significant upregulation of PPAR-γ/UCP1 in the baicalin-treated group. Further molecular docking and molecular dynamics simulations confirmed a stable interaction between baicalin and UCP1. Validation via small interfering RNA-mediated knockdown of PPAR-γ and UCP1 revealed that inhibition of the PPAR-γ/UCP1 pathway abrogated baicalin's protective effects, highlighting the critical role of this pathway in mediating baicalin's renoprotection.

CONCLUSION:

Baicalin protects against SA-AKI by activating the PPAR-γ/UCP1 signaling pathway. This study provides new insights into the mechanisms through which baicalin mitigates kidney injury in sepsis, suggesting its potential as a therapeutic agent for SA-AKI.

31 Dec 2025·PHARMACEUTICAL BIOLOGY

Antidepressant activity of flavones from traditional Chinese medicine: a meta-analysis

Review

Author: Mi, Xue ; Wang, Hanqing ; Lu, Youyuan ; Wang, Qing ; Yang, Caiyan ; Ma, Wei ; Xia, Changbo

CONTEXT:

Flavones, the key active components in Traditional Chinese Medicine (TCM), have demonstrated antidepressant activity. Given the numerous animal studies conducted, a systematic analysis is essential to provide a valuable reference for future research.

OBJECT:

This study investigated the antidepressant activity of flavones based on animal models and summarized the underlying mechanisms.

METHODS:

We systematically searched 7 bibliographic Databases as of August 12, 2023, such as Web of Science, PubMed, China National Knowledge Infrastructure, etc. The meta-analysis was performed using either the random or fixed-effect model, supplemented by trial sequential analysis (TSA). The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) approach was used to assess the quality of evidence.

RESULTS:

A total of 25 studies involving 458 mice were included, identifying five flavones (baicalin, baicalein, apigenin, luteolin, vitexin) with antidepressant activity. Compared to the control group, flavones significantly reduced immobility time in forced swimming and tail suspension tests. Flavones also decreased serum and hippocampal levels of interleukin (IL)-1β and tumor necrosis factor-alpha (TNF-α), reduced nuclear factor kappa B (NF-κB) levels, and increased brain-derived neurotrophic factor (BDNF) levels. Relative to the positive group, flavones raised IL-6, sucrose preference rate, and corticosterone (CORT) levels, with no significant differences in other factors. The TSA showed the efficacy of flavones for treating depression with adequate 'information size' for the primary outcome.

CONCLUSIONS:

The results demonstrate that flavones exert protective effects against depression in mice, primarily by stimulating neurotrophic factors and modulating inflammatory pathways. These findings emphasize their potential as promising candidates for the development of novel antidepressant therapies.

100 Deals associated with Baicalin

Login to view more data

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Hepatitis	China	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute kidney injury due to sepsis	Preclinical	China	Affiliated Hospital of Jiangnan University	12 Jun 2025
Liver Diseases, Alcoholic	Preclinical	China	Southern Medical University	13 May 2025
Immune-mediated uveitis	Preclinical	China	Shandong University of Traditional Chinese Medicene	12 May 2025
influenza A subtype H9N2 infection	Preclinical	China	Beijing University of Agriculture	08 May 2025
Lung Cancer	Preclinical	China	Fujian Provincial Hospital	05 May 2025
Lung Cancer	Preclinical	China	Fujian Medical University	05 May 2025
Lung Cancer	Preclinical	China	Fujian University of Traditional Chinese Medicine	05 May 2025
Lung Cancer	Preclinical	China	Fuzhou University	05 May 2025
Multiple Sclerosis	Preclinical	China	Henan University of Traditional Chinese Medicine	01 May 2025
Multiple Sclerosis	Preclinical	China	J&K Scientific Ltd.,	01 May 2025